Latest news for China Medicine (OTC:CHME) Stock

China Medicine Corp is a distributor of pharmaceutical and medical products in the PRC, including prescription and over-the-counter drugs, chinese herbs, traditional Chinese medicines.

News

Intraday Update

Markets

Movers

Trading Ideas

AAON

AAPL

ADBE

ADSK

AFGC

AGNC

AGRX

AGYS

AIQUY

ALTCY

ANSS

APPF

ATRC

BBSRF

BCOW

BCPC

BDUUF

BESIY

BKHYY

BRMK

BXMT

CGEN

CHME

CNBX

CPWHF

CRMT

CSLLY

CTLT

CYDY

DOOO

ECNCF

EDPFY

ELVT

ENGIY

ENLAY

EPRT

ESOCF

FATE

FOVSY

GFOO

GNRC

Granite Real Estate Inc. Stapled Units, each consisting of one unit of Granite Real Estate Trust and one common share of Granite REIT Inc.

GRP-U

GVDNY

HOLX

HTGC

IBDSF

IESC

ILPT

IVME

JFBC

Janus Henderson Group plc Ordinary Shares

KLIC

KNBIF

KNSL

KNTNF

LAMR

LFVN

LUNA

MINI

MJWL

MOBO

MSTR

MTSI

Stocks That Hit 52-Week Highs On Wednesday

Buybacks

After-Hours Center

Press Releases

China Medicine Announces Stock Repurchase Plan

CHINA MEDICINE CORP by China Medicine Corp.

China Medicine Corp

China Medicine Corporation (OTCBB: CHME), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines, and other health products, announced today that its board of directors authorized a stock repurchase program. 
The program authorizes a buyback of the company's common stock up to a value of $2.0 million. The authorization is valid through July, 2011. The program utilizes funds currently held in the escrow account pursuant to the company's agreement with its principal shareholder, OEP CHME Holdings, LLC, an affiliate of One Equity Partners, the private equity arm of JP Morgan, dated January 28, 2010.
At current price levels $2.0 million equals roughly 806,000 shares or 3.95% of the outstanding shares. 
SOURCE: China Medicine Corporation

China Medicine

China Medicine Corporation (OTCBB: CHME), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines, and other health products, announced today that its board of directors authorized a stock repurchase program. 

The program authorizes a buyback of the company's common stock up to a value of $2.0 million. The authorization is valid through July, 2011. The program utilizes funds currently held in the escrow account pursuant to the company's agreement with its principal shareholder, OEP CHME Holdings, LLC, an affiliate of One Equity Partners, the private equity arm of JP Morgan, dated January 28, 2010.

At current price levels $2.0 million equals roughly 806,000 shares or 3.95% of the outstanding shares. 

SOURCE: China Medicine Corporation

Comments

China Medicine

News

Latest news for China Medicine (OTC:CHME) Stock

Wednesday, January 29, 2020

Friday, July 09, 2010

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga